Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition

February 12, 2020 By The ASCO Post

Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune checkpoint inhibitors as standard of care in England between 2014 and 2018 (Abstract 55).

Related Content